Safety of high-dose nicotinamide: a review
- PMID: 11126400
- DOI: 10.1007/s001250051536
Safety of high-dose nicotinamide: a review
Abstract
Nicotinamide, the amide derivative of nicotinic acid, has over the past forty years been given at high doses for a variety of therapeutic applications. It is currently in trial as a potential means of preventing the onset of Type I (insulin-dependent) diabetes mellitus in high-risk, first-degree relatives. Nicotinamide is for regulatory purposes classed as a food additive rather than a drug and has not therefore required the formal safety evaluation normally expected of a new therapy. Because the safety of treatment with megadoses of vitamins cannot be assumed, a full literature review has been undertaken. The therapeutic index of nicotinamide is wide but at very high doses reversible hepatotoxicity has been reported in animals and humans. Minor abnormalities of liver enzymes can infrequently occur at the doses used for diabetes prevention. There is no evidence of teratogenicity from animal studies and nicotinamide is not in itself oncogenic; at very high doses it does however potentiate islet tumour formation in rats treated with streptozotocin or alloxan. There is no evidence of oncogenicity in man. Growth inhibition can occur in rats but growth in children is unaffected. Studies of its effects on glucose kinetics and insulin sensitivity are inconsistent but minor degrees of insulin resistance have been reported. The drug is well tolerated, especially in recent studies which have used relatively pure preparations of the vitamin. Experience to date therefore suggests that the ratio of risk to benefit of long-term nicotinamide treatment would be highly favourable, should the drug prove efficacious in diabetes prevention. High-dose nicotinamide should still, however, be considered as a drug with toxic potential at adult doses in excess of 3 gm/day and unsupervised use should be discouraged.
Similar articles
-
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.Lancet. 2004 Mar 20;363(9413):925-31. doi: 10.1016/S0140-6736(04)15786-3. Lancet. 2004. PMID: 15043959 Clinical Trial.
-
Fine structure of rat islet cell tumors induced by streptozotocin and nicotinamide.Diabetologia. 1974 Feb;10(1):37-44. doi: 10.1007/BF00421412. Diabetologia. 1974. PMID: 4365139 No abstract available.
-
A review of nicotinamide: treatment of skin diseases and potential side effects.J Cosmet Dermatol. 2014 Dec;13(4):324-8. doi: 10.1111/jocd.12119. J Cosmet Dermatol. 2014. PMID: 25399625 Review.
-
[Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationale, effects, toxicology and clinical experiences. ENDIT Group].Ugeskr Laeger. 1994 Jan 24;156(4):461-5. Ugeskr Laeger. 1994. PMID: 8140661 Review. Danish.
-
Nicotinamide in type 1 diabetes. Mechanism of action revisited.Diabetes Care. 1999 Mar;22 Suppl 2:B16-20. Diabetes Care. 1999. PMID: 10097894 Review.
Cited by
-
Cutaneous Squamous Cell Carcinoma: An Updated Review.Cancers (Basel). 2024 May 8;16(10):1800. doi: 10.3390/cancers16101800. Cancers (Basel). 2024. PMID: 38791879 Free PMC article. Review.
-
Optic Nerve Neuroprotection in Glaucoma: A Narrative Review.J Clin Med. 2024 Apr 11;13(8):2214. doi: 10.3390/jcm13082214. J Clin Med. 2024. PMID: 38673487 Free PMC article. Review.
-
A metabolic signature for NADSYN1-dependent congenital NAD deficiency disorder.J Clin Invest. 2024 Feb 15;134(4):e174824. doi: 10.1172/JCI174824. J Clin Invest. 2024. PMID: 38357931 Free PMC article.
-
The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis.Nutrients. 2023 Dec 27;16(1):100. doi: 10.3390/nu16010100. Nutrients. 2023. PMID: 38201930 Free PMC article. Review.
-
Nicotinamide restores tissue NAD+ and improves survival in rodent models of cardiac arrest.PLoS One. 2023 Sep 15;18(9):e0291598. doi: 10.1371/journal.pone.0291598. eCollection 2023. PLoS One. 2023. PMID: 37713442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous